FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutical composition, which contains parathyroid hormone (PTH), methionine, at least one SAS poloxamer and physiologically acceptable buffer preparation, which can be applied in animals and people, as well as to method of obtaining said composition and application.
EFFECT: group of inventions ensures composition solution stability and prolonged storage term.
19 cl, 11 ex, 22 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF FACTOR VII POLYPEPTIDES | 2002 |
|
RU2357751C2 |
| PHARMACEUTICAL COMPONENT BASED ON HUMAN PARATHYROID HORMONE AND INTRANASAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 2001 |
|
RU2292219C2 |
| CLOSED CONTAINER, CONTAINING ACTIVATED FACTOR VII POLYPEPTIDE METHODS OF OBTAINING IT AND SET AND METHOD OF SET APPLICATION | 2006 |
|
RU2440810C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| LIQUID WATER PHARMACEUTICAL COMPOSITION CONTAINING FACTOR VII POLYPEPTIDE | 2004 |
|
RU2388460C2 |
| STABILISED SOLID COMPOSITIONS OF VII FACTOR POLYPEPTIDES | 2003 |
|
RU2366451C2 |
| VACCINE COMPOSITIONS | 2010 |
|
RU2581020C2 |
| RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION | 2012 |
|
RU2586306C2 |
| PHARMACEUTICAL COMPOSITION OF PEMBROLIZUMAB AND USE THEREOF | 2021 |
|
RU2791857C2 |
| PREPARATIONS WITH PROLONGED RELEASE FOR INTRA-ARTICULAR ADMINISTRATION | 2018 |
|
RU2786830C2 |
